Our Company

About Us

ImmuneSensor Therapeutics is a clinical-stage biotechnology company led by a team of experienced biotech executives who are committed to creating novel treatments that harness the body’s innate immune system to treat a wide range of diseases. Leveraging the extensive versatility and therapeutic potential of the cGAS-STING pathway, we are focused on discovering and developing novel medicines that address inflammatory and autoimmune diseases, along with cancers. Our growing pipeline includes cGAS inhibitors, which work to suppress inflammation and autoimmunity as well as STING agonists, designed to elicit anticancer immunity.

Our History

Pioneers of cGAS/cGAMP

ImmuneSensor was founded in 2014 based on the seminal research conducted in the laboratory of Dr. Zhijian “James” Chen's at the University of Texas Southwestern Medical Center. In 2012, his groundbreaking discovery of the cyclic GMP-AMP synthase (cGAS) enzyme and its secondary messenger, cyclic GMP-AMP (cGAMP), quickly spawned the scientific community's interest and subsequent research into the role of the cGAS-STING pathway in innate immunity through recognizing dsDNA in the cytosol. The importance of the pathway in activating the immune system and its broad applicability in many diseases is now widely recognized and has catalyzed intense drug development in Biopharma.

Since our Company's founding in 2014 and in-licensing intellectual property from UTSW, our team has built a promising pipeline of cGAS inhibitors and STING agonists with first- and best-in-class potential.

Company Milestones



Dr. James Chen’s discovery of cGAS and cGAMP published in Science


ImmuneSensor founded based on seminal work by Dr. Chen’s lab (UTSW)


Intellectual Property portfolio in-licensed from UTSW


ImmuneSensor Laboratory started operations


Prepared IND for IMSA101, a STING Agonist


U.S. FDA cleared IND for IMSA101


IMSA101 Phase 1 trial (monotherapy cohort) initiated


2nd generation STING agonist platform technology established


IMSA101 Phase 1 (combination with checkpoint inhibitors cohort) initiated


Received $16 M CPRIT award for IMSA101 Phase 2 trials


IMSA101 Phase 1 trial completed and RP2D established


IMSA101 randomized Phase 2 trial initiated


Prepare to advance IMSB301 cGAS inhibitor to Phase 1 trial in health volunteers

Our Facility

Our headquarters and lab facilities are based in Dallas, Texas, a short distance from the world-renowned UTSW medical center. ImmuneSensor’s team of passionate and highly talented scientists and biotech professionals is proud to collaborate alongside global researchers and investigators, clinical trial facilities, corporate partners and contract research organizations.

Leadership Team

Thomas W. Dubensky, Jr., Ph.D

President and Chief Executive Officer

Jet Li

Board Chairman and Co-Founder

Lijun ‘Josh’ Sun, Ph.D

VP, Research & Development

Teresa Mooneyham

VP, Clinical Operations & Head of Project Management

Jian Qiu, Ph.D.

Director of Chemistry

Betty Lawrence

VP, Regulatory

Edward Garmey, M.D

Acting Chief Medical Officer